Shopping Cart
- Remove All
- Your shopping cart is currently empty
CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $329 | In Stock | |
5 mg | $798 | In Stock | |
10 mg | $1,090 | In Stock | |
25 mg | $1,650 | In Stock | |
50 mg | $2,230 | In Stock | |
100 mg | $2,930 | In Stock |
Description | CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction. |
Targets&IC50 | CDK4:3 nM, CDK4:3 nM , CDK6:1 nM , CDK6:1 nM |
In vitro | CDK4/6/1 Inhibitor is an anti-proliferative agent that arrests the U87MG cell line exclusively in G1 (IC50=15.3 nM in the anti-proliferation assay). U87MG cells exposed to varying concentrations of CDK4/6/1 Inhibitor for 24 hours show a dose-related increase in G1 arrest, and a significant increase in the percentage of cells in G1 is found in as little as 13.72 nM of CDK4/6/1 Inhibitor.[1] |
In vivo | In an orthotopic xenograft mouse model of glioblastoma multiforme, CDK4/6/1 Inhibitor (3.125 to 50 mg/kg) has tumor growth inhibition values ranging from 62% to 99%, and no significant body weight loss is observed. The increase in life span based on the median survival time of vehicle-treated animals in mice administered a dose of 50 mg/kg is significant at 162%.[1] |
Alias | Crozbaciclib |
Molecular Weight | 488.57 |
Formula | C28H30F2N6 |
Cas No. | 2099128-41-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: Slightly soluble |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.